CLINICAL STUDY ON CEFOTIAM HEXETIL

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement6; pp. 372 - 375
• Main Authors: MIKI, FUMIO, IKUNO, YOSHIYASU, INOUE, EIJI, MURATA, AKIHITO, TANIZAWA, SHINICHI, SAKAMOTO, KAZUO, TAHARA, AKIRA, KAWASE, YOSHIO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• Subjects: Cefotiam hexetil
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement6_372

Cefotiam hexetil (CTM-HE), a pro-drug obtained by esterification of the carboxyl group of cefotiam, was given to patients with respiratory tract infection and its efficacy and safety were evaluated. Two patients with acute exacerbation of chronic bronchitis and 3 with pneumonia were given cefotiam hexetil at an oral dose of 200 mg after meals three times a day for 7 to 14 days. One patient was excluded from evaluation because his clinical course was unknown. Clinical response was good in the 2 patients with acute exacerbation of chronic bronchitis, and in 2 patients with pneumonia, good in 1 and poor in 1. As for bacteriological effect, 2 strains of Streptococcus pneumoniae were eradicated and 1 of Haemophilus influenzae persisted. No side effects or abnormal laboratory findings were observed except slight eosinophilia in 1 patient.